Press Releases Shionogi & Co., Ltd.

Equities

4507

JP3347200002

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-05-17 am EDT			5-day change	1st Jan Change
7,129 ^JPY	-1.14%		-4.81%	+4.87%

May. 14	Japan's Nikkei drifts sideways as more earnings, US CPI awaited	RE
May. 13	Japan's Shionogi says COVID treatment did not meet endpoint in late-stage trial	RE

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Shionogi & Co., Ltd. and Maze Therapeutics, Inc. Announce Exclusive Worldwide License Agreement for MZE001, a Novel Therapeutic Candidate for the Treatment of Pompe Disease	May. 13	AQ
Shionogi - Notice of Collaboration Agreement for the Discovery and Development of Novel Malaria Preventive Drugs with Nagasaki University, National Institute of Infectious Diseases, and MMV, Supported by the GHIT Fund	May. 09	AQ
Shionogi & Co., Ltd. - Notice regarding introduction of a Restricted Stock Compensation Plan for Vice Presidents	Apr. 23	AQ
Shionogi & Co., Ltd. - Notice Regarding Completion of Cancellation of Treasury Shares	Apr. 19	AQ
ESCMID Global 2024, Shionogi presents real-world data demonstrating efficacy of Fetcroja, Fetroja in critically ill patients with certain difficult-to-treat bacterial infections	Apr. 19	AQ
Shionogi - The European Commission Grants Orphan Medicinal Product Designation for Zatolmilast, a Potential First-In-Class Treatment Being Investigated for Fragile X Syndrome	Apr. 12	AQ
Shionogi & Co., Ltd. - Recognized as One of the Highest-Ranking Companies on the Supplier Engagement Rating by CDP for the Fourth Consecutive Year	Mar. 08	AQ
Shionogi & Co., Ltd. - Notice Regarding the Status of Acquisition of Own Shares	Mar. 06	AQ
Shionogi Announces Xocova Obtained Standard Approval in Japan for the Treatment of SARS-CoV-2 Infection	Mar. 06	AQ
ViiV Healthcare presents phase I clinical trial findings of a cabotegravir long-acting injectable investigational formulation allowing at least four months between doses \| GSK	Mar. 05	AQ
Shionogi and Osaka University Establish a New Joint Research Lab on Post-COVID-19 Condition	Mar. 04	AQ
Shionogi Announces the Initiation of the Second Phase of Comprehensive Cooperation in the Field of Infectious Diseases Focused on Malaria with Nagasaki University	Mar. 04	AQ
Shionogi Announces appointment of Auditors, Corporate officers, Corporate Reorganization and Personnel Reassignment	Feb. 29	AQ
PureTech Founded Entity Akili Announces Positive Results from Shionogi's Phase 3 Clinical Trial of Localized Version of Akili's EndeavorRx for Pediatric ADHD Patients in Japan	Feb. 28	AQ
Shionogi & Co., Ltd. - Positive Results from Phase 3 Clinical trial of Digital Therapeutic App SDT-001 and Submission for Marketing Approval in Japan	Feb. 27	AQ
Akili Announces Positive Results from Shionogi's Phase 3 Clinical Trial of Localized Version of Akili's EndeavorRx for Pediatric ADHD Patients in Japan	Feb. 27	AQ
Shionogi - Announcement of the Strategic Business Partnership Agreement for Diagnosis Support AI Program in Dementia and Depression between FRONTEO and Shionogi	Feb. 15	AQ
Shionogi Announces New Phase 3 Data Showing Early Resolution of Many Common COVID-19 Symptoms in JAMA Network Open	Feb. 14	AQ
Shionogi & Co., Ltd. - Recognized with the Double a List for Leadership in Corporate Transparency and Performance on Climate Change and Water Security by CDP for the second consecutive year	Feb. 08	AQ
Shionogi & Co., Ltd. - Notice Regarding the Status of Acquisition of Own Shares	Feb. 07	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Shionogi & Co., Ltd.

Equities

4507

JP3347200002

Press Releases

Filters